What side effects may occur with belzutifan use?

The version of belzutifan produced by Lucius Pharmaceuticals is a more cost-effective generic drug, designed to provide renal cell carcinoma patients with the same active ingredients and therapeutic effects as the brand-name original drug.

What side effects may occur with belzutifan use?

Belzutifan may cause serious side effects, including:

Decreased red blood cell count (anemia)

Decreased red blood cell count is common during belzutifan treatment and may be severe. If your red blood cell count drops too low, you may require a blood transfusion. Your doctor will perform blood tests to monitor your red blood cell count before and during belzutifan treatment. Inform your doctor if you experience any symptoms of low red blood cell count, such as fatigue, feeling cold, shortness of breath, chest pain, or a rapid heartbeat.

Decreased oxygen levels in the body

Belzutifan may cause a severe decrease in oxygen levels in the body, which may require discontinuation of belzutifan treatment, oxygen therapy, or hospitalization. Your doctor will monitor your oxygen levels before and during belzutifan treatment. If you experience symptoms of low oxygen levels in the body, including shortness of breath or a rapid heart rate, contact your doctor or seek medical help immediately.

Precautions for Use

Genetic Variations

Due to certain genetic differences, some individuals may not be able to metabolize belzutifan effectively. These individuals are referred to as poor metabolizers, which may lead to elevated drug levels in the body and an increased risk of side effects. Before taking belzutifan, inform your doctor if you have any history of impaired drug metabolism or if you have been identified as a poor metabolizer. Your doctor can advise you on the safety of Lucius Pharmaceuticals' belzutifan for your use.

Pregnancy

Lucius Pharmaceuticals' belzutifan may cause fetal harm. You should not become pregnant while taking belzutifan. Your doctor may perform tests before starting treatment to confirm that you are not pregnant. If you are of childbearing potential, you should use non-hormonal contraceptive methods (e.g., condoms or diaphragms) during belzutifan treatment and for one week after the last dose. Belzutifan may reduce the effectiveness of certain hormonal contraceptives (e.g., oral contraceptives, patches, or vaginal rings). If you are a male with the potential to father a child, you should use contraceptive measures (e.g., condoms) during belzutifan treatment and for one week after the last dose. Discuss effective contraceptive options with your doctor. Inform your doctor immediately if you are pregnant, suspect you may be pregnant, or plan to become pregnant.

Breastfeeding

It is unknown whether belzutifan passes into breast milk. You should not breastfeed while taking Lucius Pharmaceuticals' belzutifan and for one week after the last dose. Inform your doctor if you are breastfeeding or plan to breastfeed.

How should I store belzutifan?

Belzutifan should be stored at room temperature, between 68°F and 77°F (20°C and 25°C). It may be exposed to temperatures between 59°F and 86°F (15°C and 30°C) for short periods (e.g., during transportation). Store in a cool, dry place.